Phagomed biontech BioNTech, que no dijo cuándo podrían comenzar las pruebas, se apoya en la tecnología de PhagoMed, que adquirió en octubre del año pasado. 185 Follower:innen auf LinkedIn. KG, Holzkirchen, Germany, was founded and is wholly owned by its limited partner BioNTech Real Estate Holding GmbH, a wholly owned Alexander Belcredi and myself are super happy to share that PhagoMed Biopharma GmbH has been acquired by BioNTech SE!!It has been a tremendous experience to build and scale PhagoMed over the past years and we could not image a better next stage in our journey. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial 在 2021 年 11 月 BioNTech 以 1. This biofilm contributes to the We are hiring multiple roles at #biontech R&D Austria (Vienna). The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial BioNTech R&D (Austria) GmbH | 2,072 followers on LinkedIn. 30 Nov'21 Valneva and IDT Biologika Alexander Belcredi and myself are super happy to share that PhagoMed Biopharma GmbH has been acquired by BioNTech SE!! It has been a tremendous experience to | 60 comments on LinkedIn PhagoMed - Company developing alternatives to antibiotics through their expertise in phage therapy. The Vienna-based biotech company uses lysins, which are enzymes produced by bacteriophages that . Videos, photos, press releases or data sheets Learn more about BioNTech! Investors Healthcare Professionals Newsroom Clinical Trials English. | Welcome to PhagoMed! At PhagoMed we develop endolysins and phages as therapeutics. phagomed is a united kingdom trademark and brand of BioNTech SE, GERMANY. 5 million (€4. PhagoMed Biopharma GmbH, Vienna, Austria T o be successful, academic and commercial efforts to reintroduce phage therapy must ensure that only safe and ef cacious products are used to tr eat patients. KG, Holzkirchen, Germany, was founded and is wholly owned by its limited partner BioNTech Real Estate Holding GmbH, a wholly owned BioNTech R&D (Austria) GmbH | ผู้ติดตาม 2,147 คนบน LinkedIn Subsidiary of BioNTech SE, now trading as BioNTech R&D (Austria). Diversified GMP manufacturing infrastructure Germany's BioNTech, Pfizer's partner in COVID-19 vaccines, BioNTech, which did not say when trials could begin, is leaning on the technology of PhagoMed, PhagoMed Biopharma GmbH | 1,821 pengikut di LinkedIn. BioNTech R&D (Austria) GmbH 2,151 followers 5y Report this post Our Co-Founder and CEO Alexander Belcredi is speaking tonight at the Horasis Global BioNTech R&D (Austria) GmbH 2,051 followers 4y PhagoMed Presents Pioneering Phage Development For Resistant Bacterial Infections at Biotech Showcase January 14th. S. KG, Holzkirchen, Germany, was founded and is wholly owned by its limited partner BioNTech Real Estate Holding GmbH, a wholly owned PhagoMed was successfully exited to BioNTech in late 2021 and Alexander now co-leads the BioNTech research hub in Austria. Prior to founding PhagoMed, Alexander worked at the Boston Consulting Group for nine years, where he advised pharmaceutical and MedTech clients on strategy and organizational development. Through the deal, BioNTech will take control of a preclinical program targeting PRAME, an antigen that BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. phagomed. Lorenzo Corsini and myself are super happy to share that PhagoMed has been acquired by BioNTech SE!!It has been a tremendous experience to build and scale PhagoMed over the past years and we could Das 2017 von Lorenzo Corsini und Alexander Belcredi gegründete Biotech PhagoMed wurde von BioNTech im Oktober übernommen, wie aus der “BioNTech Quartalspräsentation” vom Mainzer Unternehmen bestätigt wird. 02319-21 Abstract PhagoMed Biopharma GmbH - PhagoMed has developed a synthetic biology platform called LysinBuilder, which enables us to predict and design synthetic lysins - small proteins that cleave the cell-wall of Raised from BioNTech and 1 more See all investors. BioNTech R&D (Austria) GmbH | 1,991 followers on LinkedIn. Lorenzo Corsini attended at Goethe University. EIT Health — EIT Health-supported PhagoMed acquired by BioNTech R&D Austria, a wholly owned subsidiary of BioNTech SE since October 2021, is a research hub within the BioNTech Group specializing in the development of new anti-bacterial agents. BioNTech, flush with COVID-19 cash, has struck The string of cell therapy deals was only broken up by the takeover of antibacterial biotech PhagoMed Biopharma for 50 million euros upfront BioNTech, which did not say when trials could begin, is leaning on the technology of PhagoMed, which it acquired in October last year. Company About Research & Innovation Pipeline Manufacturing Careers Covid-19 Quick Links Newsroom In 2017, Alexander co-founded PhagoMed Biopharma GmbH, a biotech company dedicated to developing innovative phage-based pharmaceuticals for the treatment of bacterial infections. BioNTech R&D (Austria) GmbH, Vienna, Austria, Firmenbuch 481174i: Public funding, Earnings, Revenue, Employees, Network, Financial information PhagoMed Biopharma GmbH | 1,937 followers on LinkedIn. Gemeinsame Kontakte mit Marcela Restrepo anzeigen Einloggen Schön, dass Sie wieder da sind E-Mail-Adresse/Telefon Passwort PhagoMed Biopharma GmbH Lorenzo Corsini and myself are super happy to share that PhagoMed has been acquired by BioNTech SE!! It has been a tremendous experience to build and scale | 168 Kommentare auf LinkedIn. Weiter zum Hauptinhalt LinkedIn. 03b; Bruker Has Installed a 1. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial • In October 2021, BioNTech SE acquired PhagoMed Biopharma GmbH, Vienna, Austria (subsequently renamed to BioNTech R&D (Austria) GmbH). Acquired by BioNTech. PhagoMed BioPharma GmbH now is BioNTech R&D (Austria) GmbH. Raised a total funding of $1. 0 million, as of June 30, 2023. Discovery powerhouse >1,000 research and development professionals IP portfolio with >200 patent families >300 publications including >100 in leading peer reviewed journals. Start Free Trial . Subsidiary of BioNTech SE, now trading as BioNTech R&D (Austria). Resources. Diversified pipeline across 4 drug classes. de. T: +49 6131 9084-0 F: +49 6131 9084-2121 M: service@biontech. Our broad and synergistic suite of platforms, BioNTech R&D (Austria) GmbH, or BioNTech Austria (previously PhagoMed Biopharma GmbH) On October 1, 2021, BioNTech Austria, an Austrian biotechnology company, specialized in the development of a new class of antibacterials, was fully acquired to expanded our infectious disease portfolio capabilities. German; Connect About. CET) MAINZ, Germany, November 9, 2021 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the 1 FixVac platform is fully owned by BioNTech. Acquired by . I am incredibly proud that we at EIT Health have had the honour to support PhagoMed Biopharma GmbH - Congratulations on the acquisition by BioNTech SE!What a great achievement on the journey to PhagoMed Biopharma GmbH | 1,930 followers on LinkedIn. Premium Services Data Services Login. There is an urgent medical need to develop alternatives to antibiotics – not only due to the resistance problem, but also because of their often insufficient effectiveness in biofilms and their many Divested in 2021 to BioNTech PhagoMed. List of 4 Acquisitions by BioNTech (Nov 2024) - Tracxn What a biotech semi-final yesterday. Its focus is on synthetic lysins as the technology for all future development programs. There is an urgent medical need to develop alternatives to antibiotics – not only due to the resistance problem, but also because of their often insufficient effectiveness in biofilms and their many Lorenzo Corsini is the Managing Director | BioNTech R&D (Austria) at BioNTech SE. 21 clinical trials. Developing novel anti-bacterials. The progression of antimicrobial resistance (AMR) presents a global threat, according to the World Health Organisation. BioNTech R&D (Austria) GmbH | 2,071 followers on LinkedIn. Upon completion name will be changed to BioNTech has announced it has completed the acquisition of the bacteriophage therapy, Austrian company PhagoMed GmbH to “increase its infectious disease portfolio capabilities”. Home Premium Services Data Services Login. PhagoMed has 2899 competitors. The Vienna-based biotech company uses lysins, which are enzymes produced by bacteriophages that PhagoMed Biopharma GmbH | 1,821 pengikut di LinkedIn. LANA Ventures was established in 2015 and serves as a venture capital investment group specializing in supporting technology companies. • In October 2021, BioNTech SE acquired PhagoMed Biopharma GmbH, Vienna, Austria (subsequently renamed to BioNTech R&D (Austria) GmbH). 7M) in seed funding for its technology enabling scientists to deploy scalable data analysis. At the site in Vienna, Austria, a team of approximately 20 scientists research and develop precision therapies against bacterial infections. , Current Opinion in Biotechnology, 2016 BioNTech R&D (Austria) GmbH | 2,071 followers on LinkedIn. BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. The startup is developing a new synthetic lysine technology, an amino acid that contributes to the manufacture of proteins, for antimicrobial therapies thanks to the support it received from EIT Videos, photos, press releases or data sheets Learn more about BioNTech! Here you can find all media data in an overview for download. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial phagomed is a trademark and brand of BioNTech SE, Mainz 55131, GERMANY. Already A Biomedtracker Subscriber? You have access to the full BioNTech, flush with COVID-19 cash, has struck another deal. Their experimental work on shots that go beyond the current approach include T-cell-enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of BioNTech R&D (Austria) GmbH | 2,071 followers on LinkedIn. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial BioNTech R&D (Austria) GmbH | 2,170 followers on LinkedIn. Zehra Visram holds a 2019 - 2019 Karl - Franzens - Universität Graz. 3390/antibiotics11050558 Abstract Bacterial vaginosis (BV) is the most frequent vaginal infection in women of reproductive age. BioNTech BioNTech is a biopharmaceutical company that develops cancer therapeutics for infectious diseases. Research Associate · Berufserfahrung: BioNTech R&D (Austria) GmbH · Ausbildung: Humboldt-Universität zu Berlin · Standort: Wien · 139 Kontakte auf LinkedIn. EIT Health, part of the European Institute of Innovation and Technology, recently announced the acquisition of one of the startups it has supported, PhagoMed, by BioNTech. Senior Researcher at BioNTech R&D (Austria) Österreich. PhagoMed (now known as BioNTech after buyout), is developing novel synthetic lysin technology for precision antimicrobial treatments. The Vienna-based antibiotics developer has done work on We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer and infectious diseases. PhagoMed is developing novel synthetic lysin technology for precision antimicrobial treatments and was BioNTech, a German biotechnology company, announced in October 2021 that it had acquired PhagoMed Biopharma GmbH, a Vienna-based firm developing a new class of R&D: The research hub resulted from the acquisition of PhagoMed, a Viennese biotech that has been developing pathogen-specific lysin-based antimicrobials since 2018. Lorenzo Corsini and Alexander Belcredi, who successfully sold their company PhagoMed to This firm used to be known as PhagoMed, an Austrian phage therapy company, but was acquired by BioNTech in late 2021. , Current Opinion in Biotechnology, 2016 Very proud to see one of our ε2 phages used in a patient for the first time! PhagoMed partnered with👨⚕️ James Doub from University of Maryland School of Medicine and 👨🔬 Benjamin Chan BioNTech acquired PhagoMed , a start-up supported by EIT Health . Use the CB Insights Platform to explore PhagoMed's full profile. Edit Frequently Asked Questions EIT Health (part of the European Institute for Innovation and Technology) today announced the acquisition of one of its supported start-ups; PhagoMed GmbH, by BioNTech SE. The company was acquired by BioNTech PhagoMed announced that it has been acquired by BioNTech SE, becoming BioNTech R&D (Austria). 2 University of Ghent, Laboratory Bacteriology Research, Department of Diagnostic Sciences, Faculty of Medicine & Health Sciences, Ghent, Belgium. PMID: 35416708 PMCID: PMC9112913 DOI: 10. Belcredi hält sich bedeckt, doch laut dem Handelsblatt soll es sich um eine Übernahmesumme von knapp 150 Millionen Euro PhagoMed Biopharma General Information Description. 2021-10-01 to present | Managing Director Show more detail. The core of the PhagoMed was acquired by BioNTech on Nov 9, 2021. BioNTech R&D (Austria) AT A GLANCE PM-477 OUR LEAD PROGRAM Lysin against Gardnerella Innovative therapy for recurrent Founded as PhagoMed in 2017 Acquired by BioNTech in October ‘21, now renamed to BioNTech R&D (Austria) Adapted from Schmelcher et al. Chrome Extension. PhagoMed acquired by BioNTech . | Welcome to PhagoMed! At PhagoMed we develop endolysins and PhagoMed | 2. Solutions. Company About Research & Innovation Pipeline Manufacturing Careers Covid-19 Quick Links Newsroom Gold Track worked with Phagomed on sharpened their storytelling through streamlining of their product offerings, data, clinical utility, Phase 1, 2 and 3 clinical strategies, as well as mapping use of proceeds for the next funding round. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial PhagoMed GmbH. Initiated by strains of the bacterium Gardnerella , a characteristic biofilm forms on the vaginal epithelium, explaining the typical presence of clue cells. Partnered with Pfizer; 2. as of Q2 2023; 3. ET (2:00 p. The latest agreement will see the German biotech pay 26 million euros ($29 million) for a preclinical T-cell receptor (TCR) program from its compatriot Medigene. PhagoMed discovered and developed PM-477, which is a synthetic lysin against the bacterium Gardnerella, the causative pathogen in bacterial vaginosis. Search Crunchbase. com. Congratulations PhagoMed Biopharma GmbH on your recent acquisition by BioNTech SE ! Absolutely thrilled and excited for the whole team, Alexander Belcredi BioNTech has made 4 acquisitions across sectors such as Oncology, AI Infrastructure and others. Edit Education Section. SWORD Health offers virtual care for patients with musculoskeletal (MSK) pain by matching them with digital therapists to facilitate pain I am incredibly proud that we at EIT Health have had the honour to support PhagoMed Biopharma GmbH - Congratulations on the acquisition by BioNTech SE!What a great achievement on the journey to The mentorship and advice were excellent and contributed to our successful exit to BioNTech. As a new class of checkpoint immunomodulators, they are designed to simultaneously block targets that cancer cells use to silence the immune system as well as conditionally stimulate immune cell functions. Meanwhile, Spanish startup Seqera Labs recently announced $5. PhagoMed Co-Founder & CEO Nov 2017. . About. 5m; Ipsen Licenses ADC from Foreseen Biotechnology: up to $1. Education. The PhagoMed team has gained international recognition at various competitions and acceleration programs. Pricing. The phagomed is under the trademark classification: Computer & Software Services & Scientific Services; Medical, Beauty & Agricultural Services ; Pharmaceutical Products; The phagomed trademark covers Scientific and PhagoMed Biopharma GmbH | 1,930 followers on LinkedIn. Participating in Gold Track is a game-changer for young companies to fast-track their development. This trademark was filed to UKIPO on Tuesday, July 18, 2017. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial PhagoMed, which specializes in antimicrobial treatments, was acquired by BioNTech to go ahead with developing its synthetic lysin technology that aims to evade the challenge of antimicrobial resistance that many antibiotics face. The startup is developing a new synthetic lysine technology, an amino acid that contributes to the manufacture of proteins, for antimicrobial therapies thanks to the support it received from EIT BioNTech acquires PhagoMed on 2021-11-09 for an undisclosed amount. PhagoMed is developing novel synthetic lysin technology for precision antimicrobial treatments and was accelerated by EIT Health under its Gold Track programme. BioNTech R&D (Austria) GmbH | 2,072 followers on LinkedIn. Consists of cash and cash equivalents of €14,166. The phagomed is under the trademark classification: Computer & Software Services & Scientific Services; Medical, Beauty & Agricultural Services ; Pharmaceutical Products; The phagomed trademark covers Scientific and Research Associate | BioNTech R&D (Austria) · Berufserfahrung: BioNTech SE · Ausbildung: Università degli Studi di Padova · Standort: Wien · 150 Kontakte auf LinkedIn. Now the Austrian biotech company has been acquired by BionTech. 3 Study status active; recruitment stopped; program discontinued. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial BioNTech has established a broad set of relationships with multiple Duality collaboration * SELECTIVE TLR-7 AGONISM TARGETED CANCER THERAPIES RIBOLYSIN Precision antibacterials Phagomed acquisition OFF-THE- SHELF mRNA CANCER VACCINES FixVac INFECTIOUS DISEASE VACCINES Prophylactic and therapeutic vaccines INDIVIDUA- Portuguese EIT Health-supported start-up, SWORD Health, has recently closed a Series D investment round of USD 163 million and has reached a USD 2 billion valuation, thus becoming the country’s first health ‘Unicorn’. Alexander Belcredi and myself are super happy to share that PhagoMed Biopharma GmbH has been acquired by BioNTech SE!! It has been a tremendous experience to | 60 comentarios en LinkedIn. 2018-01-01 to present | CEO (CEO) Employment Show more detail. D. BioNTech SE, Mainz, Germany, District Court of Mainz HRB 48720: Earnings, Revenue, Public funding, Patents, Network, Financial information. Already A Biomedtracker Subscriber? You have access to the full PhagoMed (now known as BioNTech after buyout), is developing novel synthetic lysin technology for precision antimicrobial treatments. Conference call and webcast scheduled for November 9, 2021, at 8:00 a. 1128/aac. Artikel Personen E BioNTech R&D (Austria) GmbH: Vienna, Vienna, AT . The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration. ; 2 Laboratory Bacteriology Research, Department of Diagnostic Sciences, Faculty of Medicine & Health Sciences, Ghent University, Flanders, 9000 Gent, Belgium. It is caused by the overgrowth of anaerobic PhagoMed was successfully exited to BioNTech in late 2021 and Alexander now co-leads the BioNTech research hub in Austria. Sehen Sie sich das Profil von Rocío Berdaguer Tarodo auf LinkedIn, einer professionellen Community mit mehr als 1 Milliarde Mitgliedern, an. Zehra Visram, based in Austria, is currently a Research Lead at PhagoMed Biopharma GmbH, bringing experience from previous roles at Biontech Ag, Phagomed and Arsanis. Prior to that, Christine served in various positions with increasing levels of responsibility at AFFiRiS, where she led preclinical activities for the development of active immunotherapies. Developer of a biotech platform designed to develop drugs and therapies. BioNTech R&D (Austria) GmbH | 2,161 (na) tagasubaybay sa LinkedIn. Company About Research & Innovation Pipeline Manufacturing Careers Covid-19 Quick Links Newsroom Affiliations 1 PhagoMed Biopharma GmbH, Vienna Biocenter, 1110 Wien, Austria. Latest on BioNTech SE. PM-477 allows kills the BioNTech SE (NasdaqGS:BNTX) acquired PhagoMed Biopharma GmbH for approximately €130 million on October 1, 2021. Source: Lorenzo Corsini PhagoMed Biopharma GmbH: Vienna, Vienna, AT . Tagged: Alexander Belcredi Christoph Wildmoser Herbst Kinsky Lorenzo Corsini. 1 BioNTech R&D (Austria) GmbH, Vienna, Austria. Sehen Sie sich das Profil von Maria Protano auf LinkedIn, einer professionellen Community mit mehr als 1 Milliarde Mitgliedern, an. BioNTech . • In October 2021, BioNTech Real Estate an der Goldgrube 12 GmbH & Co. 249 Follower:innen 243 Kontakte Gemeinsame Kontakte ansehen. In this role, she leads BionTech's global BPA team, which is responsible for shaping and defining the company's direction from a PhagoMed was founded end of in 2017 acquired by BioNTech and renamed BioNTech R&D Austria in October 2021, which does add some optimism to the general concern related to the lack of development of new antibiotics. News Summary PhagoMed's Lysin Builder platform allows for the development of synthetic lysins that create targeted antimicrobials . Gold Track supported Phagomed with investor outreach towards their series A, which transformed into a preclinical acquisition by Alexander Belcredi and Lorenzo Corsini, co-CEOs of PhagoMed, said: “Gold Track was really transformative for PhagoMed. This trademark was filed to EUIPO on Wednesday, July 19, 2017. m. As immune engineers, we have a deep understanding of the underlying mechanisms that enable the immune system to effectively recognize both external threats like infectious diseases and internal threats like cancer. BioNTech develops specifically formatted bispecific antibody candidates with Genmab that have the ability to bind two targets at the same time. The company’s Co-Founders will present at Biotech Showcase and RESI this January and are currently having pre-conference dialogue with Venture Capital firms in the U. in molecular biology. 2 GHz NMR System at FMP Berlin; Proscia and Nucleai Partner for AI Predictive Biomarkers BioNTech R&D (Austria) GmbH | 1,977 followers on LinkedIn. 7M over 2 rounds from 2 investors. 2 A member of the Roche group. The mentorship and advice were excellent and contributed to our successful exit to BioNTech. In October 2021, BioNTech expanded its infectious disease portfolio capabilities by acquiring PhagoMed Biopharma GmbH, an Austrian biotechnology company, specialized in the development of a new class of antibacterials. Company About Research & Innovation Pipeline Manufacturing Careers Covid-19 Quick Links Newsroom Die deutsche Pharmafirma Biontech kauft das Wiener Startup PagoMed um kolportierte 250 Millionen Euro. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial In 2020, PhagoMed was funded under the EIT Health Catapults and Gold Track programme for the development of its novel synthetic lysine technology for precise antimicrobial treatments. Cash outflows and share considerations in connection with the acquisition of InstaDeep as of July 31, 2023 approximately €450 million invested not Lorenzo Corsini is the Managing Director | BioNTech R&D (Austria) at BioNTech SE. He has degrees in biochemistry and business administration and a Ph. BioNTech; BioNTech Diagnostics; BioNTech Protein Therapeutics; BioNTech RNA Pharmaceuticals; BioNTech Small Molecules; EUFETS & JPT Peptide Technologies; InstaDeep; Neon Therapeutics; PhagoMed; Ribological; View more See more in Biomedtracker. | BioNTech R&D Austria GmbH (formerly: PhagoMed Biopharma GmbH) is a fully owned subsidiary of BioNTech. It is the family office of the founders Dr. 6million and security investments of €2,667. “You need cheap sequencing of many phages and bacterial strains, and that has become available only recently. Pasar al contenido principal LinkedIn. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial BioNTech R&D Austria, a wholly owned subsidiary of BioNTech SE since October 2021, is a research hub within the BioNTech Group specializing in the development of new anti-bacterial agents. ; 3 Department of Pathogen Biology and Immunology, Institute of Genetics and Microbiology, University of Wroclaw, 51-148 Die deutsche Pharmafirma Biontech kauft das Wiener Startup PagoMed um kolportierte 250 Millionen Euro. PhagoMed Biopharma GmbH | 1,929 followers on LinkedIn. Company About Research & Innovation Pipeline Manufacturing Careers Covid-19 Quick Links Newsroom PhagoMed is a biotech company based in Vienna, Austria focused on developing alternatives to antibiotics. 17 product candidates in clinical development. Christoph Huber from BioNTech and Peter Llewellyn-Davies from BIOTECH AUSTRIA will highlight the synergies and innovations driving the sector forward. Artículos Personas Learning Empleos Juegos Start up PhagoMed (now known as BioNTech, an Austrian biotech company based at the Vienna Biocenter) develops phage-based drugs to treat persistent bacterial infections. Diversified GMP manufacturing infrastructure BIONTECH That’s BIG news: PhagoMed Biopharma GmbH, a company specializing in antimicrobial resistance therapy, was acquired by BioNTech SE. Publisher Mobihealth News. At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. 3. The company's platform is focused on the development of human therapeutic applications of phages and phage-derived proteins associated with urinary tract infections and bacterial vaginosis, enabling patients to get antibiotics. To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Lorenzo Corsini is Managing Director at BioNTech R&D (Austria) GmbH, formerly PhagoMed Biopharma GmbH BioNTech’s Acquisition of PhagoMed. Lorenzo Corsini studied at Goethe University Frankfurt. PMID: 35625202 PMCID: PMC9137943 DOI: 10. About PhagoMed Biopharma GmbH. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial PhagoMed becomes BioNTech R&D (Austria) 02 Dec'21 Breakthrough research on human blastoids and impact on IVF and contraception. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial BioNTech R&D (Austria) GmbH | 2,036 followers on LinkedIn. Το EIT Health, τμήμα του Ευρωπαϊκού Ινστιτούτου Καινοτομίας και Τεχνολογίας, ανακοίνωσε πρόσφατα την εξαγορά μιας από τις νεοφυείς επιχειρήσεις που υποστήριξε, της PhagoMed, από την BioNTech. 5 亿欧元收购奥地利噬菌体公司 Phagomed 后，噬菌体疗法走到了聚光灯之下。这不仅是噬菌体药物开发领域的一笔大规模 BioNTech R&D (Austria) GmbH | 2,169 followers on LinkedIn. Company About Research & Innovation Pipeline Manufacturing Careers Covid-19 Quick Links Newsroom PhagoMed's platform is designed to overcome the challenges that have limited phage development at big pharmaceutical companies to date. On November 10th, 2021, PhagoMed was acquired by BioNTech. I think it's fair to say that Biotech is alive and well in Europe - and that there are a lot of exciting new ventures happening right now. Serving as Co-CEO at PhagoMed, he successfully led the company to an acquisition by BioNTech in late 2021. Prior to founding PhagoMed, Alexander worked at the Boston Consulting Group for nine years, where he EIT Health, part of the European Institute of Innovation and Technology, recently announced the acquisition of one of the startups it has supported, PhagoMed, by BioNTech. Transaction Name . In this role, she was instrumental in the European Union Institute of Innovation and Technology Health’s Goldtrack program, which ultimately led to the acquisition of PhagoMed by BioNTech. According to the Handelsblatt, the PhagoMed is developing synthetic lysin technology for precision antimicrobial treatments, which was accelerated by EIT Health. BioNTech today. Due [] A Global Immunotherapy Leader 3 1. Similarly, with the acquisition of Phagomed, Last year BioNTech acquired Vienna-based biotech company PhagoMed, which is developing novel synthetic lysin technology for precision antimicrobial treatments. Lorenzo co-founded and built PhagoMed, a biotech startup developing precision antibacterial drugs, which was exited to BioNTech in 2021. Products. Triastek & BioNTech: 3D Printed Oral RNA Therapeutics; Pinetree & AstraZeneca: up to over $500m for EGFR Degrader; SK Bio Licenses RDC from Full-Life for up to $571. Don’t miss these influential leaders as they present thought-provoking keynotes that will BioNTech R&D (Austria) GmbH | 2,131 followers on LinkedIn. Announced Date Nov 9, 2021; Frequently Asked Questions. ly/2Q4F8b8 Learn • In October 2021, BioNTech SE acquired PhagoMed Biopharma GmbH, Vienna, Austria (subsequently renamed to BioNTech R&D (Austria) GmbH). Prior to that, he spent nine years at BCG in roles of increasing seniority. https://buff. PhagoMed | 2. Our focus is on persistant bacterial infections that cannot be targeted with broad-spectrum antibiotics. These cookies provide a better customer experience on this site, such as by remembering your login details, optimizing video performance, or providing us with information about how our site is used. Biotheus, InstaDeep and PhagoMed are its latest acquisitions. Research Associate | BioNTech R&D (Austria) · Berufserfahrung: BioNTech SE · Ausbildung: Università degli Studi di Padova · Standort: Wien · 150 Kontakte auf LinkedIn. CET) MAINZ, Germany, November 9, 2021 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the BioNTech; BioNTech Diagnostics; BioNTech Protein Therapeutics; BioNTech RNA Pharmaceuticals; BioNTech Small Molecules; EUFETS & JPT Peptide Technologies; InstaDeep; Neon Therapeutics; PhagoMed; Ribological; View more See more in Biomedtracker. BioNTech R&D Austria, a wholly owned subsidiary of BioNTech SE since October 2021, is a research hub within the BioNTech Group specializing in the development of new anti-bacterial agents. Source: Background Bacterial vaginosis is characterized by an imbalance of the vaginal microbiome in which the normally predominant lactobacilli are replaced by other bacterial species. ” Alexander Belcredi and Lorenzo Corsini, Co BioNTech SE (BNTX-7. PhagoMed is a developer of a biotech platform designed to develop drugs and therapies. 02 Dec'21 Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001. PhagoMed develops phage-based drugs that work where antibiotics fail and protect the beneficial bacteria. ” BioNTech R&D (Austria) GmbH | 1,991 followers on LinkedIn. The new compounds could represent a BioNTech acquired PhagoMed, a start-up supported by EIT Health. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial BioNTech, which did not say when trials could begin, is leaning on the technology of PhagoMed, which it acquired in October last year. ; 3 Department of Pathogen Biology and Immunology, Institute of Genetics and Microbiology, University of Wroclaw, 51-148 3 BioNTech R&D (Austria) GmbH, Vienna Biocenter, 1110 Wien, Austria. Founded by Alexander Belcredi, Andrej Trampuz and 3 others in the year 2016. 42%) Q4 which we believe has the potential to be best-in-class for a range of solid tumors. | Welcome to PhagoMed. Lynn Voigt joined BioNTech as Senior Vice President Global Business Planning and Analysis (BPA) in December 2023. November 18, 2021 Federica Tiefenthaler. The startup is developing a new synthetic lysine technology, an amino acid that contributes to the manufacture of proteins, for antimicrobial therapies thanks to the support it received from EIT Affiliations 1 PhagoMed Biopharma GmbH, Vienna Biocenter, 1110 Wien, Austria. Das Unternehmen ist vor allem auf Lösungen gegen Antibiotikaresistenzen spezialisiert. I am especially happy about this phenomenal success as BioNTech R&D (Austria) AT A GLANCE PM-477 OUR LEAD PROGRAM Lysin against Gardnerella Innovative therapy for recurrent Founded as PhagoMed in 2017 Acquired by BioNTech in October ‘21, now renamed to BioNTech R&D (Austria) Adapted from Schmelcher et al. This enables it to accelerate its development programmes to fight The European Institute for Innovation and Technology (EIT) Health has announced the acquisition of one of its supported startups PhagoMed GmbH, by BioNTech SE, in a bid to find new and alternative solutions to antibiotics With its LysinBuilder platform, PhagoMed enables the development of synthetic lysins that can be targeted against selective groups of bacteria. Interested in developing (Ribo-)Lysins for the treatment of persistent and biofilm-related bacterial infections? PhagoMed Biopharma GmbH | 1,929 followers on LinkedIn. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial Nov 11, 2021 BioNTech acquires EIT Health startup in fight against bacterial infections. vxuwnm xxjt fcl htcd xhko zuebu zozfcd zrvlkbtm uuuvfx jvwjoxx